Lipella pharmaceuticals to present phase 2a data for lp-310 in oral lichen planus at 2025 aaom/eaom international meeting

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented presentation scheduled for thursday, may 15, 2025, at 11:36 a.m. pt pittsburgh, may 15, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella,” “we,” “our,” or the “company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing phase 2a trial of lp-310 (liposomal tacrolimus oral rinse) for the treatment of oral lichen planus (olp) will be presented at the 2025 joint international meeting of the american academy of oral medicine (aaom) and the european association of oral medicine (eaom) in las vegas.
LIPO Ratings Summary
LIPO Quant Ranking